M. Chaix

HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)

M. Ziol, C. Delaugerre, C. Katlama, 2022, AIDS Research and Therapy.

Comparative performance of the Biocentric Generic Viral Load, Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and m2000 Abbott assays for quantifying HIV-1 B and non-B strains: Underestimation of some CRF02 strains.

C. Rouzioux, L. Meyer, N. Lerolle, 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

C. Delaugerre, P. Aegerter, G. Peytavin, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

National survey of the prevalence and conditions of selection of HIV‐1 reverse transcriptase K70E mutation

V. Calvez, C. Delaugerre, S. Yerly, 2008, Journal of medical virology.

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

R. Tubiana, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome

C. Giaquinto, J. Darbyshire, A. Babiker, 2004, AIDS.

Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

V. Calvez, C. Charpentier, C. Delaugerre, 2019, The Journal of antimicrobial chemotherapy.

First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022

V. Calvez, Y. Yazdanpanah, J. Pawlotsky, 2022, Infectious diseases now.

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)

V. Calvez, C. Charpentier, C. Delaugerre, 2018, The Journal of antimicrobial chemotherapy.

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study

R. Tubiana, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen

V. Calvez, C. Charpentier, P. André, 2018, The Journal of antimicrobial chemotherapy.

Does transient HAART during primary HIV-1 infection lower the virological set-point?

Laurence Meyer, Faroudy Boufassa, C. Rouzioux, 2004, AIDS.